Valeria Dionisi 

Wonderful start on #ESTRO2026. Honored to have been invited as speaker in the Lung session, along with excellent speakers like M.Putora and F.Schneiders. A huge thanks to @finn_corinne,@gerryhanna &Anna Britten for their superb moderation on a the pre clinical bootcamp #estro26

PACIFIC remains one of the hardest standards to beat in unresectable stage III #NSCLC. Adding concurrent nivolumab ± ipilimumab to CCRT failed to improve PFS or OS versus standard durvalumab consolidation — while increasing pneumonitis. More IO ≠ better IO. 🫁 @OncoAlert @MedicalwatchHQ @MedwatchKate @OncoReporte @Lung_Cancers @LungCancerEu @LungCancerRx @OncBrothers @Larvol

🚨 Save the Date! 🫁 Excited for this joint webinar from the @EORTCLung Cancer Group & @EORTC_QLG on integrating #QoL and #PROs into #LungCancer #ClinicalTrials. 🌐 Register here: us06web.zoom.us/j/85859872255?…

Let’s kickoff ESTRO26 with the Pre-Clinical Bootcamp. Looking forward to the wonderful speakers for differents topic #estro26 #preclinicalbootcamp #lung

✨ Meet Our Social Media Ambassadors for the #ESTRO26 Congress ✨ We’re proud to introduce our 41 Social Media Ambassadors, each specialising in a specific area. 🔍 Find the ambassadors aligned with your interests 👉 Discover the full team and start following.

Amici miei, servono penne di insulina per diabetici tipo 1 da mandare a Cuba. Servono anche striscie reattive per analizzare diversi parametri nelle analisi delle urine, tra cui la microalbuminuria nei pazienti vascolari cronici. Chi può aiuti! Anche un rt! Grazie mille!❤️💪🇨🇺

@Corriere Che titolo squallido, che brutta fine per il corriere della sera

La «passione» delle sinistre per Francesca Albanese: premi e onori dalla Spagna alla Francia trib.al/pa9TfDB

@tarotdori Sì

🚨SON DAKİKA: Yarın sabah uyandığında telefonunu kontrol et — şimdiye kadar aldığın en güzel haberlerden birini alacaksın. Bu işareti görmezden gelme. “EVET” yazarak enerjiyi onayla. ✨

🚨🚨Multiple Brain Mets Randomized Trial🚨 · Significantly less symptom burden with SRS compared to HA-WBRT · Better ADL, cognition & KPS after SRS · SRS Standard of Care 5-20 brain mets jamanetwork.com/journals/jama/…

tanto arriverà gianfranco che guadagna a stento €1200 al mese che dirà che è un'ingiustizia intollerabile per chi si è meritato la possibilità di avere un jet privato

Gruber "si deve dimettere Nordio?" Travaglio "dovrebbe già essere ai giardinetti...se mettiamo in fila i suoi capolavori...Almasri, arresti col preavviso, depenalizzazione reato ufficio, corte dei conti e il referendum...se Meloni lo tiene noi ci divertiamo" #Minetti #ottoemezzo

Intervista di Elly Schlein su “ El Pais” 😎

20 years of progress in lung cancer care 👇 Advances in imaging, radiotherapy, tumor biology, and systemic therapy have transformed NSCLC and SCLC treatment. In the #JTO20 series, Salama et al. explore the evolving role of radiotherapy. Read more: bit.ly/4cnLyxg

First-line #EGFR+ #NSCLC is rapidly evolving with more effective systemic strategies. But is there a “third way” of intensification? In our meta-analysis just published in @JTOonline, integrating LAT with EGFR TKIs significantly improved PFS and OS with acceptable safety. ➡️ Upfront integration in 1L may be where LAT expresses its full potential. Grateful to all co-authors and especially @Brunet3Leon for leading this effort. @dplanchard @BRicciutiMD @JuliaRotow @APassaroMD @thenasheffect @AminNassarMD @adib_elio @GiuliaLaCavaMD @valentsant @RobertoFerrara_ @HendriksLizza @finn_corinne @FabianAckerMD @derosa__lisa @IASLC @PoliclinCampus @CampusBioMedico @ImperialSandC 🔗 jto.org/article/S1556-…

L'inviato speciale di Trump, Paolo Zampolli diffida #Report dal mandare in onda l'inchiesta che lo riguarda. Il servizio tratta degli #Epsteinfiles e #MelaniaTrump e andrà in onda ugualmente questa sera alle 20.30. Sosteniamo #Report e i giornalisti veri.

Great discussions at the EORTC Lung Cancer Group meeting in Gdańsk. A real privilege to work with such a collaborative and forward-thinking community—especially encouraging to see new voices actively contributing to study design and research priorities. You are welcome!! #EORTC

Stage III NSCLC, real-world study 4 strategies 3y Overall survival 53% (C/IO→RT) ↑T4/N3) 56% (CRT→IO) 37% (C/IO) 82% (C/IO→surgery) RT ≥54 Gy 88.6%, 90day mortality 5.3% Already happening. Outcomes will depend on patient selection clinical-lung-cancer.com/article/S1525-… @OncoAlert

E comunque di Elly Schlein ognuno può pensare quello che vuole ma la sua storia politica è innegabile, è fatta di studio ed esperienze di altissimo spessore, cosa che non possono dire certi outsider costruiti in laboratorio.

Texas lung cancer day 2: What is the role of radiotherapy vs. surgery in stage III NSCLC in the era of IO? In the debate about RT @SalmaJabbour1 vs. surgery @BrendonStilesMD, RT won in the case of T4 N2M0 NSCLC. Representatives from RT and Surgery did a great job inspiring lung cancer colleagues about optimizing local TX with novel systemic TX. Ultimately, we need to answer the question of what we can/should offer to our patients, including our family members. Congratulations on a very successful @IASLC @TLCconference